Patient and Caregiver Insights Are Key to Improving Adherence 4

Lilly employee Coleman Gerstner presents a concept for improving adherence at the Adherence Summit.

Lilly employee Coleman Gerstner presents a concept for improving adherence at the Adherence Summit.

 

Savin Pic a 8-2-13The following post is by Ken Savin, Advisor, Clinical Innovation at Eli Lilly and Company. Ken received his Ph.D. from the University of Utah in 1996 and came to Lilly in 1998 from the Memorial Sloan Kettering Cancer Research Center as a senior organic chemist. He worked on several projects as a medicinal chemist in the areas of anxiety, depression and inflammatory disorders, and he has been involved in many cross-functional Lilly research collaborations. Some of Ken’s recent efforts include the NASA – Lilly collaboration, an outgrowth of the InnoCentive program and a recent Innovation Day event. Through these programs, he continues to reach out to other organizations internally and externally as part of a broader open innovation effort.

Every day we see some evidence that the culture of medicine is changing. Paternalistic approaches to providing healthcare are becoming less and less acceptable as patients have begun to make good use of the medical information and community support networks available on the Internet. If we, as drug developers, want to provide the best possible care and the best possible medicines, it just makes good sense for us to listen to people and carefully consider what works best from their standpoint.

Adherence, the idea of whether or not a patient is following a treatment regimen as directed, is one of many complex issues within drug development for which we could use more insights from patients and caregivers. It has been estimated that three out of four Americans do not take their medications as prescribed. Even in clinical trials, where adherence rates tend to be relatively high, investigators report average adherence rates of only 43 to 78 percent among patients receiving treatment for chronic conditions. This can lead to poor health outcomes for patients, and unreliable results in a clinical trial.

More…

ePatients Tweet Their #ChronicLife 1

Chronic Life Word Cloud

In the early 90s, Britt Johnson‘s life was like that of any healthy young girl. Until suddenly, it wasn’t. In the summer of 1992, Britt came down with strep throat for the first of what would be many times. Over the next several months, Britt encountered one health setback after another. Months of health setbacks turned into years, during which time Britt had repeated contact with the healthcare system. This contact was not always positive. Britt received a series of misdiagnoses and was even accused of being a hypochondriac. Finally, at the age of 20 Britt was diagnosed with Psoriatic Arthritis. Britt’s disease has continued to progress, and her diagnosis has been amended to Spondyloarthropathy and Rheumatoid Arthritis.

More…

Learning From Those Touched By Rare Disease 1

Rare Disease Day

Our most rare or unique qualities can often be our greatest strengths, but when it comes to disease, rarity is a tremendous challenge. A rare disease, also known as an orphan disease, is any disease that affects a small percentage of people. In the United States, a disease is considered rare if it affects fewer than 200,000 people at any given time. According to the National Institutes of Health (NIH), there are more than 6,800 rare diseases. Though each of these diseases are rare, having a rare disease of some sort is not. Approximately 30 million Americans, or almost one in every 10 people, suffer from a rare disease.

Living With a Rare Disease

The numbers cited above are interesting, but they don’t tell the whole story. The rest of the story relates to the daily struggles of rare disease patients and their support networks. Rare disease symptoms vary even among patients suffering from the same disease. This symptom variability, combined with lack of scientific understanding and awareness, can lead to delayed diagnosis and difficulty accessing treatment. Patient quality of life is severely affected by the “loss of autonomy due to the chronic, progressive, degenerative, and frequently life-threatening aspects of the disease.”

More…

Rahlyn Gossen’s Unique Perspective On Clinical Trials 1

Rahlyn GossenWe’re privileged to be working with Rahlyn Gossen, founder of Rebar Interactive, a digital strategy consultancy serving the clinical research industry. Rebar Interactive creates empowering (and award-winning) digital experiences for patients and professionals. Rahlyn’s digital marketing expertise spans a variety of areas, including search, social media, and mobile. Her work is infused with a patient-centric perspective, honed during Rahlyn’s time as a clinical research coordinator.

Rahlyn publishes a widely-read clinical trial blog and newsletter focusing on digital strategy, the patient experience, and innovation. The same topics are explored in 140 characters or less on Rebar Interactive’s Twitter account. Rahlyn also serves on the editorial advisory board of Applied Clinical Trials. Rahlyn is a proud New Orleanian and a connoisseur of cute online animal videos, particularly those of the feline variety.  

Tell me a little bit about yourself, and the path you’ve been on to make clinical research better.

More…